Review of the Ubiquitin Role in DNA Repair and Tumorigenesis, with Emphasis in Breast Cancer Treatment; Current Data and Future Options by Mourtzoukou, Despoina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Review of the Ubiquitin Role in DNA Repair and
Tumorigenesis, with Emphasis in Breast Cancer
Treatment; Current Data and Future Options
Despoina Mourtzoukou, Ioannis Drikos,
Nikolaos Goutas and Dimitris Vlachodimitropoulos
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.72600
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Despoina Mourtzoukou, Ioannis Drikos, Nikolaos Goutas 
and Dimitris Vlachodimitropoulos
Additional information is available at the end of the chapter
Abstract
Breast carcinoma remains the commonest carcinoma among women worldwide. Despite 
the fact that impressive progression has been achieved so far regarding pathophysiol-
ogy, histopathology and treatment of this cancer, there are still undiscovered fields on 
molecular and therapeutic levels. The need of resolving problems such as chemoresis-
tance, recurrence and metastasis has led in revealing key molecules in the development 
and progression of malignancies, including breast tumors. In this review, we will briefly 
describe the functions of ubiquitin and post-translational modifications (PTMs) focusing 
specially in DNA repair and then discuss about the implication of ubiquitin and related 
molecules in tumorigenesis and specifically in breast carcinoma. So far there are only 
few drugs approved by FDA that target the ubiquitin system. There will be an analysis 
regarding the current and potential anti-cancer therapeutic strategies based on targeting 
specific ubiquitin-related molecules.
Keywords: ubiquitin, DNA repair, deubiquitinating enzymes, breast carcinoma,  
target therapy
1. Introduction
Breast cancer is the most common carcinoma and the second cause of death among women 
worldwide. Incidence rates vary greatly worldwide from 19.3/100,000 women in Eastern 
Africa to 89.7/100,000 women in Western Europe. Although age-adjusted breast cancer mortal-
ity rates have declined by 36% from 1989 to 2012, the incidence of this carcinoma is increasing 
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due to increase life expectancy and adoption of western lifestyle [1]. In US, during 2015 there 
were 231,840 new cases of invasive carcinoma, 60,290 new cases of in situ carcinoma and 
40,290 deaths due to breast cancer, for women of all age groups [2, 3]. As of March 2017, 
there are more than 3.1 million women with a history of breast cancer in the US; this includes 
women currently being treated and women who have finished treatment [4].
This increase explains the interest for research in depth for mechanisms of tumor progression 
and subsequently for potential therapeutic drugs. During the last years, there has been progress 
in understanding the histopathology and molecular biology of breast carcinoma, but still there 
are many unanswered questions to be solved. The complexity of interaction between internal 
and external factors that lead to the evolution of breast cancer cells is evident via the variety 
of the clinical, morphological, histopathological and molecular characteristics of this malig-
nancy. Currently, there are many therapeutic tools that in combination with surgery offer bet-
ter survival rates and quality of life for breast carcinoma patients, including hormonotherapy, 
radiotherapy, chemotherapy and targeted monoclonal antibody therapy (Trastuzumab and 
Herceptin), depending on the tumor stage and receptors expression in each patient [4]. Despite 
improved treatments that have been achieved, many breast tumors are not eradicated effectively 
due to their resistance—intrinsic or acquired—or relapse following initial response, resulting in 
metastasis at later stages and subsequently to patient death. This outcome suggests that further 
understanding of the molecular mechanisms underlying the development of breast cancer is 
essential to identify new therapeutic agents and achieve better treatment. In recent years, there 
is an increasing interest and investigation regarding potential targets for molecular therapy. 
One of the most promising field concerns the different levels of ubiquitin system, however, so 
far there are only a handful of drugs targeting this system that have been approved by the FDA.
Mammalian cells maintain their homeostasis regarding cell cycle control through prolifera-
tion and apoptosis signals that lead to specific protein expression. Ubiquitination is one of the 
PTMs that are involved in a variety of complex cellular processes such as endocytosis, cell 
cycle progression and activating to inactivating substrates. The ubiquitin system regulates the 
majority of cellular activities via proteolysis and/or signal transduction—modulating protein-
protein interactions and participates in DNA damage repair. DNA repair not only has a cru-
cial role regarding cell cycle control, proliferation and apoptosis but also in diseases, tumor 
progression and even metastasis of malignant neoplasms, including breast carcinoma [5].
2. General features and functions of ubiquitin
The genome of the organisms can be modified by epigenetic alterations, except for the DNA 
sequence of genes. Epigenetic modifications include DNA methylation, histone modifications 
(methylation, acetylation, phosphorylation, sumoylation and ubiquitination) and non-coding 
RNAs that lead to changes in gene expression [6]; in addition, PTMs regulate the cellular 
functions of most proteins—the best studied of which include phosphorylation, acetylation 
and ubiquitination—with constant interplay among them. All the aforementioned changes 
can influence both normal and disease states of an organism and are reversible. There is an 
interplay between PTMs on target proteins and the attachment or removal of PTMs can deter-
mine the substrate fate [7].
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Ubiquitin is a 76-amino acid protein that is expressed in eukaryotic cells and is involved in the 
cell cycle regulation by proteolysis and/or signal transduction, while the majority of cellular 
activities are regulated with the involvement of the ubiquitin system [8].
The ligation of ubiquitin molecules to substrate proteins leads either to their degradation 
or can also change the substrate activity, localization and affinity to binding partners or 
even lead to other non-proteolytic processes [9]. Three enzymes catalyze the attachment 
of ubiquitin to a target protein: E1 activating enzyme, E2 conjugating enzyme and E3 
ligase [8–10].
In general, the target protein is subjected to degradation with the involvement of 26S protea-
some, a large multi-enzyme complex [8, 10].
The progress in novel technologies has provided information about the structure and function 
of the ubiquitin and thanks to the latest mass spectrometric techniques our understanding of 
the complexity and diversity of the polyubiquitin chains has increased; proteins can be modi-
fied at one or more lysine (K) residues with either a single ubiquitin molecule—mono- and 
multi-monoubiquitination, respectively—or with ubiquitin polymers—polyubiquitilation. 
Ubiquitin moieties can be conjugated through one of their lysine residues (K6, K11, K27, K29, 
K33, K48 and K63) or the N-terminal methionine residue (M1). There can be homotypic and 
Scheme 1. Variety of Ub roles in cellular processes, regarding chains and linkage types.
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heterotypic chains, by single or mixed linkage types, respectively, and chains can be branched; 
also, ubiquitin molecules can be modified by PTMs (e.g. acetylation and phosphorylation) [9].
The process of ubiquitination is reversible thanks to deubiquitinating enzymes (DUBs) that 
count to approximately 100 in the human genome and are classified into at least 6 families 
(Ub-specific proteases, Ub carboxy-terminal hydrolases, ovarian tumor proteases, Machado-
Joseph disease protein domain proteases, metalloenzymes and monocyte chemotactic pro-
tein-induced proteases) [11, 12]. The ubiquitin code through all these complex steps are 
involved not only in many biological processes such as DNA damage repair, apoptosis, cell 
cycle control, differentiation, but also in diseases, including carcinogenesis [12]. A lot have 
been achieved so far in our understanding but there are still many to be solved in the analysis 
of the numerous different roles of the ubiquitin code (Scheme 1, [13-15]).
3. Ubiquitin and DNA repair
3.1. Ubiquitin and cell cycle control
Ubiquitin is an essential, highly conserved protein expressed in various cells. It can be found 
in either free form or covalently attached to a target protein [16–18]. Ub by acting as cellu-
lar signal controls a wide range of biological processes including protein degradation, DNA 
repair, endocytosis, autophagy, degradation, immunity and inflammation.
Ub, E1, E2 and E3 enzymes are successively required to target certain substrate for degradation. 
Ub is attached to specific substrates in a three-step mechanism, with distinct enzymes catalyz-
ing each step. During first activating step, Ub becomes covalently conjugated to the side chain 
of an E1-cysteine via its carboxy-terminal (C-terminal) glycine in an ATP-dependent reaction. 
Activated Ub is transferred via E2-enzyme (ubiquitin-conjugating enzyme) at C-terminal gly-
cine residue of Ub at an internal cysteine. Finally, Ub bound E2 interacts with an E3 Ub ligase 
that catalyzes Ub transfer from E2 to a specific target protein [19, 20].
The specificity of Ub signaling is accomplished due to association of the molecule with differ-
ent substrates (mono- and poly-ubiquitination) [21]. The activity of protein molecules depends 
on the interacting region with Ub (UBD – ubiquitin binding domain) affecting intracellular 
signaling pathways [22, 23]. Monoubiquitination plays an important role in the recognition of 
double-strand breaks (DSBs). K63 linked chains of Ub are involved in the production of signal-
ing processes during DNA repair [24, 25]. The ubiquitin/proteasome system (UPS) is a main 
regulator of protein stability and plays an important role in execution of DNA damage response 
(DDR). Several studies using proteasome inhibitors validated UPS as a valuable therapeutic tar-
get in cancer [26, 27].
Recognition of DNA damage sites by Ub accumulation can be detected immediately during 
DNA damage [28]. Ubiquitination of H2A, H2B and H2AX is crucial in order to promote 
destabilization of nucleosomes [29, 30]. Monoubiquitination of H2A from RNF2-BM1 cluster 
seems to be essential for transcriptional repression of RNA-PoI II [31]. RNF2-BM1 is also 
involved in monoubiquitination of H2AX at K119 and K120 (E2: UbcH5C), which initiates 
recruitment of the apical PI3K-related kinase ATM (ataxia telangiectasia mutated) [32, 33].
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DNA repair process induces cell cycle arrest by non-homologous recombination (NHEJ) and 
phosphorylated p53. The p53 cooperates with the ATM/ATR and induces cell cycle arrest 
by activating apoptosis [34]. The ubiquitin selective Cdc48/p97/VCP affects Ddr protein 
and participates in ubiquitination and activation of degradation via proteasome [35–37]. 
Consequently, the interaction of ubiquitination and phosphorylation mechanism modulates 
the activity of many proteins such as p53.
Cell cycle procedures and DNA repair mechanisms are crucial for the genetic stability in all 
eukaryotic cells [38]. The NHEJ process reunites free ends of the DNA with relatively restricted 
homology [39]. The NHEJ process can be considered as less robust procedure according to 
reconnection of non-complementary ends of the chaperone activity such as DNA-PK, which 
remove the mismatched nucleotides [40].
The cell cycle control procedure and the reliability of the progress of NHEJ depend on the 
presence of NHEJ DNA repair proteins such as Ku70/80 and ligase XRCC4-IV [41, 42]. Besides 
NHEJ, the process of homologous recombination (HR) is also crucial for the genetic stability 
during predominantly S and G2 cell phases demonstrated the recombination of sister chroma-
tids or intact homologous chromosomes [43].
Protein ubiquitination plays an important role during DNA repair process, as several different 
molecules of the cell cycle are ubiquitinated such as 53BP1. The 53BP1 protein promotes NHEJ and 
HR activation and the protein interaction with BRCA1 during HR [44]. The binding of the protein 
to the double-strand break (DSB) region is associated with activity of the RNF8 protein. K63 acts as 
E3 ubiquitin ligase and catalyzes the ubiquitination of substrate proteins via RNF8 [45].
During DNA damage, RNF8 binds to the damage site interacting with MDC1 and catalyzes 
monoubiquitination of H2A and H2AX through action of K63. The monoubiquitination of his-
tones promotes RNF8-dependent recruitment of a second E3 ligase RNF168 at the DSB [46, 47]. 
The polyubiquitination of H2AX further promotes the recruitment of RNF168 which amplifies 
the RNF8 dependent histone ubiquitination by K63 [47, 48]. The interaction of complex RNF8/
RNF168/K63 affects the accumulation of DNA repair proteins such as BRCA1 and 53BP1.
53BP1 cannot directly bind to K63 according to absence of any relevant binding site [49]. For 
accumulation of 53BP1, p97 activation is necessary in order to remove L3MBTL1 protein to 
the DSBs sites. The p97 binds to the ubiquitinated L3MBTL1 in chromatin, affecting the bind-
ing of 53BP1 [35].
According to these, RNF8 ubiquitinates K48-dependent substrates such as JMJD [50], protein 
of NHEJ KU 80 [28] and polymerase DNA (PCNA), which are crucial for DNA repair proce-
dure [51]. These proteins may be removed from chromatin by the action of the proteasome.
Polyubiquitination of PCNA may change cellular signaling of significant molecules [52]. This 
regulator leads to waterfall ubiquitination during the DDR. During this phase, PCNA mono- 
or poly-ubiquitinated at K164 residue regulates DNA repair process [53, 54]. BRCA1 plays a 
key role through BRCA1—BRCT domain for the cell cycle progression [55]. BRCA1 reveals E3 
ubiquitin ligase activity which is vital for genomic integrity [56, 57].
p53 has already been identified as an important molecule for cell cycle progression. The RITA 
(enabler of p53 and induction of tumor apoptosis) is a small molecule that blocks p53 action [58]. 
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However, it appears to be dependent by ubiquitin even if in pro-apoptotic stage has been described 
as p53 independent [59, 60]. Nowadays, small molecules are designed to prevent the interaction 
between the p53 and MDM2, affecting in this way cell cycle control or apoptosis [61].
3.2. The importance of ubiquitin to cellular apoptosis
Besides the activation of DNA repair, the apoptotic response determines cellular integrity 
[62]. DNA damage responses depend on operation of p53 as a key factor of cell function. 
p53 is an important component of the mitochondrial apoptosis and plays a crucial role in the 
coordinated cell death by DNA damage processes.
The expression of pro- and anti-apoptotic proteins such as members of Bcl2 family is decisive 
for DDR signaling. The ability of apoptosis of immune cells is crucial for cellular differentia-
tion. Almost 90% of pre B and T cells reveal apoptosis during maturation [63].
In this process, UBE2C regulates the correct alignment of chromosomes during mitosis. 
Overexpression of UBE2C has been detected in many cancers including breast, colon, prostate, 
ovary, thymus, uterus and lung. Expression varies during the cell cycle and peaks at pro-meta-
phase and is reduced into anaphase [64, 65]. Suppression of expression of UBE2C contributes 
in tumor progression and regulates chromosome segregation during mitosis in various malig-
nancies (cancer tissues). Overexpression of UBE2S and HIF1a is detected in various tumors 
such as liver, colon cancer, breast cancer and metastatic cholangiocarcinoma [66, 67].
There are approximately 600 E3 ubiquitin ligases encoded by human genome and the mecha-
nism of ubiquitination depends on conserved catalytic domains [68, 69]. E2 and E3 ubiquitin 
ligase activity contribute to aberrant oncogenic signaling, metastasis and resistance to chemo-
therapy. STUB1 molecule demonstrated E3 ubiquitin ligase activity in cancer cells enhanced 
by limited expression of STIP1. The STUB1 operates as a complex with other proteins and 
promotes control of different regulatory molecules such as c-myc and SRC-3 through ubiq-
uitination. The restricted expression of STUB1 regulates the signaling of NFkB and the 
anti-apoptotic proteins Bcl2 and AKT, enhancing the process of inflammation and cellular 
metastasis. STUB1 is E3 ubiquitin ligase which modulates the stability of the p65 subunit of 
NFkB in cell colon cancer lines [70, 71].
Negative regulation of expression of STUB1 affects the activity of the p65 subunit and increases 
VEGF, cyclin D1, c-Myc, IL-8 and MMP-2 by the action of NFkV involved in angiogenesis and 
cancer metastasis. According to cell lines of pancreatic cancer, STUB1 has tumor suppressor 
activity and regulates the stability of EGFR via proteasomal degradation mediated by tyro-
sine kinase receptor (RTK). The STUB1 regulates phosphorylation of EGFR at Tyr845 and 
Tyr1068 positions, activating signaling pathways of PI3K/AKT and Src/FAK. Downregulation 
of STUB1 increases oncogene signaling of EGFR and enhances action of RTK inhibitor, erlo-
tinib, leading to apoptosis in vivo. STUB1 modulates proteasomal degradation of NFkB and 
the EGFR in several volumes [72–74].
The ultimate central goal of conventional cancer therapy is the effective elimination of tumors 
by DNA damage-induced apoptosis (DDIA) since the balance of protein abundance and func-
tionality are decisive for DDR. Deregulation of ubiquitin-signaling pathways is intimately 
associated with tumorigenesis and therapy resistance [60].
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Accumulating recent evidence conclusively identified ubiquitin signaling as a valuable target 
in DDR and cancer chemoresistance. The majority of these efforts focused on the regulation of 
p53 as one of the central determinants of DDR outcomes. Accordingly, an increasing number 
of specific regulators of p53 have been identified and evaluated as therapeutic target.
RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule that 
blocks p53 [58]. p53 regulates cell cycle control in different tissues including myelomas [60]. 
MI-63 and MI-219 molecules can block the interaction between p53 and MDM2, demonstrat-
ing that p53 mediates the disruption process of the cell cycle or apoptosis in tumor cells [61].
3.3. The importance of ubiquitination in the evolution of cell proliferation
Ubiquitination is a crucial post-translational modification that regulates cell cycle progres-
sion. Proteins that show E3 ubiquitin ligase activity such as SCFSKP2, SCFFBW7 and APC/C 
are responsible for coupling ubiquitin in different specific proteins affecting proteasome and 
regulation of degradation.
Many proteins with E3 ligase activity may operate either as oncoproteins or as tumor sup-
pressors. SKP2 is an oncoprotein involved in cell cycle progression through interaction with 
cyclins, p27kip1 inhibitors and p21WAF/Cip1 complex [75, 76]. The identification of related 
E3 ligases and their substrates may be important therapeutic options for cancer treatment. 
Molecules such as RNF115 and BRCA2 reveal ubiquitin E3 ligase activity overexpressed in 
estrogen receptor (ER)-positive tumors [77].
A recent study showed that BRCA2 directly interacts with RCL [78]. The BRCA1 and BRCA2 
are key molecules for the cell cycle control interacting with a large number of other factors 
including Rab7, UBC9 and hHR23a 14-3-3s [79, 80]. Several studies have also shown that 
protein p21 show ligase E3 activity interacting with SCFSkp2, CRL4Cdt2 [81], the APC/
CCdc20, MKRN1 and RNF126; BRCA2 promotes proliferation of ER-positive breast cancer 
cells through its interaction with p21 [82, 83].
In eukaryotic cells, CDKs activation is controlled by the availability of other cyclins and mol-
ecules, for example, p21, p27 and p57. Deregulation procedures of cyclins or CDKs determine 
cell cycle control and proliferation, affecting cancer progression. The process and effect of ubiq-
uitin through regulation of proteasomal activity also plays a critical role in cell cycle control [84].
BRCA2 has E3 ubiquitin ligase activity inducing ubiquitination of p21 protein. Alterations of 
BRCA2 activity affect and promote proliferation of breast cancer cells. BRCA2 activity is influ-
enced by estrogen through ER receptor activity in MCF-7 cells [78]. It has also been found that 
BRCA2 is expressed at high levels in ER-positive breast cancers in MCF-7 and T47D cell lines.
BRCA2 reveals 46% homology to SEQ RNF126, affecting the activity of p21 [83]. Both BRCA2 
and RNF126 interact with the p21. This complex may promote ubiquitination of the protein 
[82, 83]. BRCA2, RNF126 and other E3 ligases coordinately regulate the expression levels 
of p21. Except for p21, many other proteins interact with BRCA2 including Rab7, tetherin, 
UBC9, hHR23a and 14–3-3 s [82, 83]. However, BRCA2 does not appear to affect proteins 
degradation via ubiquitin mediation. BRCA2, by the action of an Ub ligase E3, induces prolif-
eration of breast cancer cells via the ubiquitination of p21 and its degradation via proteasome.
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3.4. Ubiquitin and tumor progression: Metastasis
Overexpression of E2 molecules in tumor metastasis plays an active role in regulating cell 
cycle progression and inflammation processes. In cases of defective expression of E3 ubiquitin 
ligases, the oncogene signaling, metastasis and resistance in chemotherapy are elevated.
Downregulation of ubiquitin E3 ligase in cancer is associated with STUB1 action. STIP1 is an 
escort molecule which regulates the cell cycle control and promotes ubiquitination of regula-
tors of the cell cycle such as c-Myc and SRC-3. Reduced expression and downregulation of 
expression of STUB1 and NFkB activates signaling of anti-apoptotic proteins, for example, Bcl-
2- and AKT-promoting inflammation, cell survival, cellular infiltration and metastasis [70, 71].
The reduced expression of STUB1 in colon cancer is associated with reduced degradation of 
the subunit p65 and increased expression of NFkB and molecules of cyclin D1, c-myc, IL-8 
and MMP-2 involved in angiogenesis and procedure of metastasis [85]. In pancreatic cancer, 
STUB1 is a tumor suppressor and regulates the stability of EGFR via proteasomal degrada-
tion. In addition, decreased expression of STUB1 increases oncogenic signaling of EGFR in 
pancreatic cancer cells by limiting the response of RTK, erlotinib, affecting tumorigenesis [86].
Interaction of UBE2N/UBE2V1 affects metastasis in breast cancer cells. UBE2N shows ubiquitin 
ligase activity interacting with the cofactor UBE2V1 and induces ubiquitination in Lys63 residue 
activating NFkB during inflammation. UBE2N is overexpressed in many tumors such as breast, 
pancreatic, colon, prostate, ovarian and lymphoma. UBE2N is important molecule in the process 
of metastasis of breast cancer cells to the lung by activating TGFb mediated by TAK1 and p38 [85].
It has been shown in several studies that UBE2N E2 ubiquitin ligase (UBE2V1) is overexpressed 
in breast cancer cells and increases penetration and migration. Breast cancer cells are charac-
terized by increased expression of metalloproteinase-1 (MMP1) via activation of NFkB [87, 88].
UBE2V1 inhibition via shRNAs reduced breast tumor progression and metastasis in vivo. 
Molecules with E3 ubiquitin ligase activity have been determined in pluripotent cancer stem 
cells. Pluripotent cancer stem cells are characterized by overexpression of the embryonic stem 
cell markers SOX2 (SRY-2), Oct4 (Octamer-4) and Nanog. These transcription factors are key 
regulators of pluripotency and of the inhibition of cellular differentiation. Specific indicators 
in the surface of cancer cells CD133 and CD44 are associated with increased resistance to che-
motherapy. E3 ligases control cell differentiation by regulation of expression of these specific 
proteins in different cancer types [89].
4. Ubiquitin-related molecules and breast cancer; target therapy
4.1. p53/MDM2
In about 50% of human malignancies there is mutation of TP53, making this “genome guard-
ian” the most frequently mutated gene in cancer [90, 91]. In addition, for most cancers lacking 
mutation, the wild-type p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral 
proteins that lead to its degradation. For these reasons, there is a great interest regarding targeting 
these molecules for the cancer treatment and during the last years several compounds have 
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become available that can restore wild-type properties of p53 for TP53-mutated malignancies or 
prevent the binding of MDM2/MDM4 to wild-type p53, thereby blocking its degradation in a 
variety of malignancies; the disparity provides distinct therapeutic opportunities for targeting 
cancers with p53 wild-type than those with p53 mutant cancers. Several preclinical studies have 
demonstrated that reconfiguration of mutant, to its normal, active WT p53 conformation, restores 
apoptosis and promotes tumor regression (88). Although the overall frequency of p53 mutation in 
breast cancer is approximately 20–30% (70–80% are TP53 wild-type), certain types of it are associ-
ated with higher frequencies, for example, in carriers of germline BRCA1 and BRCA2 mutations, 
strikingly, in typical medullary breast carcinomas, p53 mutation occurs in 100% of cases [92, 93]. 
In addition, TP53 mutation distribution is highly linked to molecular breast tumor subtypes found 
in 26% of luminal tumors (17% of luminal A and 41% of luminal B), in 50% of HER2-amplified 
tumors, in 69% of molecular apocrine breast carcinomas and in 88% of basal-like carcinomas [93].
In general, patients carrying a TP53 missense mutation, leading to expression of a mutant p53 
protein in the germline, have a significantly earlier cancer onset than patients with mutations 
in TP53 that result in loss of p53 protein expression. Mutant p53 has been shown to play a role 
in many different cellular processes, for example, proliferation, invasion, increased migration, 
genomic instability, cell survival, angiogenesis, EMT, stem cell dedifferentiation and drug 
resistance. The tumor suppressor role of wild-type p53 is undoubtable, but studies showed 
that mutated p53 can result in both loss of wild-type activity and gain of a novel functions, 
promoting tumorigenesis and a more aggressive tumor profile [94]. The strategies that are 
currently being explored to target mutant p53 include small molecule compounds that spe-
cifically restore wild-type conformation and transcriptional activity of mutant p53, induce 
depletion of mutant p53, inhibit the downstream pathways of oncogenic mutant p53 and 
induce synthetic lethality to mutant p53 [95, 96]. The fact that most mutant p53s are expressed 
at very high levels in cancer cells, leading to their immunohistochemical detection, makes 
these proteins very attractive therapeutic targets.
4.1.1. Hsp90 inhibitors: geldanamycin, 17-AAG and ganetespib
Blocking the function of heat shock protein 90 (Hsp90) leads to depletion of several oncogenic 
proteins such as ErbB2 and mutant p53, because Hsp90 contributes to the accumulation of 
mutant p53 by inactivating p53 ubiquitin ligases, MDM2 and CHIP [95]. Geldanamycin is 
one of the most potent and effective hsp90 alpha inhibitor and is used to target breast can-
cer; however, it failed to move into the clinics due to the toxicity associated with its solubil-
ity. Geldanamycin was modified chemically to develop 17-AAG and later 17-DMAG, which 
have higher solubility and lesser toxicity [97]. Nonetheless, in order to achieve better efficacy 
against breast cancer, a more potent, soluble and least toxic analogues need to be developed 
such as an analogue and geldanamycin-based polymeric magnetite nanocomposite; the latter 
plays a vital role in efficacious therapy, showing selective cell kill of cancerous breast cells, 
while vanquishing normal cells and hepatic toxicity [98]. Another Hsp90 inhibitor, ganes-
tespib, has proved to have little effect on wild-type p53 levels and induces mutant p53 deple-
tion with increased apoptosis in tumors in vivo in both p53R248Q Hupki (human p53 knock-in) 
and p53R172H knock-in mouse models. Ganetespib is under evaluation in clinical trials, 
supported by preclinical evidence of its potent anti-tumor activity in different breast cancer 
subtypes; a phase II trial of single agent ganetespib was conducted in patients with unselected 
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metastatic breast cancer. The clinical activity was notable in patients with trastuzumab-refrac-
tory HER2+ and triple negative breast cancer. In addition there was evidence of tumor shrink-
age, specifically in patients with lung metastases. In that trial ganetespib was well tolerated, 
thus responses in more targeted populations harboring specific HSP90-dependent oncopro-
teins justify its further study [99].
4.1.2. Histone deacetylase inhibitors (vorinostat/SAHA, romidepsin/depsipeptide, belinostat)
Histone deacetylases (HDACs) are a group of enzymes that remove acetyl groups from 
histones and regulate expression of tumor suppressor genes such as p53. HDAC inhibitors 
(HDACi) have the potential to disrupt multiple signaling pathways to inhibit tumor growth 
and induce apoptosis. HDAC inhibitors are differentiated by their structure and further 
characterized into different subgroups [100]. Specifically, suberoylanilide hydroxamic acid 
(SAHA, also known as vorinostat), a FDA-approved HDACi that inhibits class I, II and IV 
HDACs, induces degradation of mutant p53 by inhibiting HDAC6 activity, an essential posi-
tive regulator of Hsp90 and subsequent disruption of the HDAC6/Hsp90/mutant p53 complex, 
leading to mutant p53 ubiquitination by MDM2 and CHIP. SAHA shows higher cytotoxic 
effects on cancer cells carrying mutant p53 than those having wild type or null for p53. SAHA 
also sensitizes cancer cells to a topoisomerase inhibitor camptothecin in a mutant p53-depen-
dent manner. Currently, all three drugs approved by FDA (vorinostat (SAHA), romidepsin/
depsipeptide (Istodax)) and belinostat (Beleodaq) are being further evaluated for other than 
hematological malignancies and for solid tumors, either as a single agent or in combination 
with other drugs. Specifically, investigation of romidepsin for the treatment of inflammatory 
breast cancer revealed that it potentially induced destruction of IBC tumor emboli and lym-
phatic vascular architecture. Also, a combination of depsipeptide and gemcitabine was tested 
in patients with advanced solid tumors including pancreatic, breast, NSCLC and ovarian and 
the study identified a dose level of 12 mg/m2 romidepsin and 88 mg/m2 gemcitabine for phase 
II trial [101]. Clinical trials studying the combination of chemotherapy or hormone therapy 
and HDAC inhibitors show promising efficacy. [100].
4.1.3. Beclin1
Autophagy is an important intracellular catabolic mechanism that mediates the degrada-
tion of cytoplasmic proteins and organelles. We report a potent small molecule inhibitor of 
autophagy named “spautin-1” for specific and potent autophagy inhibitor-1. Spautin-1 pro-
motes the degradation of Vps34 PI3 kinase complexes by inhibiting two ubiquitin-specific 
peptidases, USP10 and USP13 that target the Beclin1 subunit of Vps34 complexes. Beclin1 is a 
tumor suppressor and frequently monoallelically lost in human cancers. Interestingly, Beclin1 
also controls the protein stabilities of USP10 and USP13 by regulating their deubiquitinat-
ing activities. Since USP10 mediates the deubiquitination of p53, regulating deubiquitination 
activity of USP10 and USP13 by Beclin1 provides a mechanism for Beclin1 to control the levels 
of p53 [102]. One study provided a molecular mechanism involving protein deubiquitina-
tion that connects two important tumor suppressors, p53 and Beclin1, and a potent small 
molecule inhibitor of autophagy as a possible lead compound for developing anti-cancer 
drugs. Actually, since Beclin 1 is expressed in breast cancer cells, it could be a unique effective 
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drug target for the prevention and treatment of breast cancer. However, the expression of 
Beclin 1 varies according to cancer molecular subtypes, and Beclin 1 is involved in both breast 
cancer suppression and tumor progression; therefore, the decision of using a Beclin 1 inducer 
or inhibitor should be made based on breast cancer stage and subtype [103].
4.1.4. Nutlin-3a
In 2004, a small molecule antagonist of Mdm2 was discovered, known as Nutlin-3a or Nutlin. 
The discovery of nutlin-3a, the first in a class of small molecule MDM2 inhibitors that binds to 
MDM2, preventing its association with and degradation of p53, has led to an extensive list of 
related compounds. Preclinical modeling with nutlin-3a showed improved anti-cancer activ-
ity in combination with cytotoxic- and molecular-targeted therapies, in many tumor types; 
the high rate of MDM2 overexpression in ER-positive breast cancer, and the ability of MDM2 
inhibitors to ubiquitinate steroid hormone receptors, has led to the evaluation of this class of 
drugs in combination with endocrine therapies [104]. It has also been shown that p53 activa-
tion with nutlin in combination with fulvestrant, a selective ER degrader, leads to a greater 
degree of apoptosis in vitro. However, the subsequent toxicity of the combination partner 
plays critical role for the success of such an approach clinically.
Also, there has been shown the potential of Nutlin-3 or similar drugs as treatment options to 
overcome chemoresistance due to cancer stem cells (CSCs) [105]. In a recent study, patient-
derived xenografts were used, as a clinically relevant model of numb-deficient breast can-
cers; the unlimited self-renewal and high tumorigenic/metastatic potential of cancer stem 
cells in numb-deficient carcinomas could be selectively reverted by re-expression of the 
tumor suppressor numb, or pharmacological restoration of p53 function with the Nutlin-3. 
Targeting the numb/p53 dysfunction selectively interferes with the CSC compartment of 
numb-deficient BCs, with only modest effects at the level of the bulk tumor population. The 
combined use of Nutlin-3 with standard chemotherapy (paclitaxel), increases the response 
to therapy of numb-deficient breast carcinomas and prevents tumor relapse after therapy 
discontinuation [106].
4.1.5. RING finger protein 31 inhibitors
The atypical E3 ubiquitin ligase RNF31 (other names HOIP and ZIBRA) is highly expressed 
in breast cancer, decreasing p53 stability, whereas depletion of RNF31 in breast cancer 
cells causes cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. 
Furthermore, RNF31 is associated with the p53/MDM2 complex and facilitates p53 polyu-
biquitination and thus its degradation, suggesting that RNF31 regulates cell death. As p53 
wild type tends to appear in ERα-positive breast cancers (Luminal A and B), there is still little 
known about RNF31 in HER2 type or triple negative breast cancers. Analysis of publically 
available clinical data sets displayed a negative correlation between RNF31 and p53 target 
genes, including IGFBP3 and BTG1, consistent with the fact that RNF31 regulates p53 func-
tion in vivo as well, findings suggesting RNF31 as a potential therapeutic target to restore 
p53 function in breast cancer [107, 108]. A lot need to be investigated by future studies on the 
development of drug targets (RNF31 inhibitors) and their clinical application.
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4.2. CDKs – CDIs
Cell cycle regulation has been identified as an attractive target for targeted drug therapy 
of cancer. Several compounds of CDK inhibitors entered preclinical and early clinical trials 
including first- and second-generation agents that are more specific to certain CDKs.
4.2.1. Palbociclib and related molecules
The results with broadly acting CDK inhibitors (first-generation inhibitors such as flavopiridol) so 
far were largely disappointing. The second-generation compounds have shown more potent activ-
ity against their targets and a more favorable safety profile. Recent preclinical and clinical studies 
using a novel (oral) reversible CDK4/6 inhibitor, palbociclib, have shown the role of CDK4/6 as a 
potential target in estrogen receptor-positive (ER+) breast carcinoma. Specifically palbociclib (PD-
0332991) has recently received accelerated Food and Drug Administration approval for the treat-
ment of hormone receptor-positive (HR+) metastatic breast cancer in combination with letrozole, 
while further data suggest improved outcome when combined with fulvestrant (hormonother-
apy). In addition to palbociclib, two other small molecule CDK4/6 inhibitors are currently in clini-
cal development, ribociclib (LEE011) and abemaciclib (LY2835219); actually the FDA has approved 
the CDK 4/6 inhibitor ribociclib (Kisqali) for use in combination with an aromatase inhibitor for the 
frontline treatment of postmenopausal women with HR+, HER2-negative advanced breast cancer 
[109, 110]. Finally, treatment with the CDK4/6 inhibitor abemaciclib has been approved by FDA in 
2017, for HR + and HER2 – advanced or metastatic breast carcinoma [111].
4.3. SCF complex – SKP2/p27
4.3.1. SKP2 inhibitors
It has been proved that Skp2 is frequently overexpressed in a variety of human cancers includ-
ing breast carcinoma; actually both Skp2 mRNA and protein display elevated levels in breast 
cancer cell lines and primary breast tumors. Therefore, inhibition of Skp2 may be a novel 
strategy for the prevention and/or treatment of this malignancy. Specific drugs that inactivate 
Skp2 in breast cancer are unavailable so far, although there is renewed interest in developing 
Skp2 inhibitors for breast cancer treatment.
It is noteworthy that several natural compounds have been found to downregulate Skp2 
expression in human cancers—including breast cancer—such as curcumin, lycopene and 
quercetin. All-trans retinoic acid (ATRA) promoted the ubiquitination of Skp2 in breast can-
cer cell lines, leading to cell cycle arrest. Gallic acid markedly reduces cell growth of human 
breast cancer cells and induces cell cycle arrest by inhibiting Skp2, attenuating Skp2–p27 asso-
ciation and reducing p27 ubiquitination. Moreover, Huang et al. (2008) reported that epigallo-
catechin-3-gallate (EGCG), the main constituent of green tea, inhibits human breast cancer cell 
growth via downregulation of Skp2 expression and accumulation of p27 among others. Both 
tamoxifen and paclitaxel significantly and synergistically enhanced cell growth inhibition by 
EGCG mediated through the downregulation of Skp2 expression in breast cancer cells [112].
In addition, siRNA gene silencing—an important gene function analysis method widely 
used in molecular studies—could be useful tool in inhibiting Skp2 activity. At the cell level, 
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siRNA interference technology is characterized by a shorter action cycle and fewer side 
effects, and can silence multiple genes specifically with minimized side effects. In a recent 
study, two pairs of SKP2-specific siRNA, siRNA1 and siRNA2, were designed and synthe-
sized and detected the endogenous SKP2 expression inhibitory effect in breast cancer cells 
MDA-MB-231. Western blotting showed that SKP2-specific siRNA1 can effectively inhibit 
endogenous SKP2 expression in these cells. Moreover, SKP2 silence significantly reduced 
breast cancer cell MDA-MB-231 proliferation. This study could be the experimental basis for 
further investigation and potential clinical application [113].
4.4. Histone ubiquitination
Monoubiquitination is one of the largest histone PTMs, alongside smaller and better studied 
modifications such as methylation, acetylation and phosphorylation. Monoubiquitination 
of histone H2B at lysine 120 (H2Bub1) has key roles in transcription, the DNA damage 
response and stem cell differentiation. Global levels of monoubiquinated histone H2B 
(H2Bub1) are low to absent in advanced cancers including breast, colorectal, lung and para-
thyroid, marking H2Bub1 and the enzymes that regulate it as key molecules in new thera-
peutic strategies for the treatment of cancer. More specifically, H2Bub1 levels were found to 
be significantly reduced in malignant and metastatic breast cancer cells, proving its tumor 
suppressor role [114].
4.4.1. USP44 inhibitors
USP44 is a subunit of the N-CoR complex and deubiquitinates H2B in vitro and in vivo. ChIP 
experiments confirmed that USP44 recruitment reduces H2Bub1 levels at N-CoR target loci; 
USP44 high expression correlates with reduced levels of H2Bub1 in the breast cancer cell 
line MDA-MB-231 and is required for efficient invasiveness of triple negative breast cancer 
cells—highly expressed in aggressive breast cancer MDA-MB-231 cells, leading to low global 
H2Bub1 levels and contributing to the invasiveness of these cells. On the contrary, depletion 
of USP44 impairs the invasiveness of MDA-MB-231 cells in vitro and causes an increase of 
global H2Bub1 levels [115]. In recent years, studies are looking for negative regulators of 
DUBs such as USP44 and USP22, to be used as therapeutic agents for malignancies, including 
mammary carcinoma, but there are still a lot to be discovered in this field for an anti-cancer 
regiment to be suggested [116].
4.5. Estrogen receptor
On a molecular basis, for example, gene expression profile, the breast carcinomas are clas-
sified into five major subtypes: luminal A and B, HER2-enriched, triple negative (basal-like 
and non-basal-like). Each of these tumors has different risk factors, response to treatment and 
disease progression/preferential metastasis sites. In addition, the etiology, pathogenesis and 
prognosis of breast cancer are significantly influenced by intrinsic molecular breast cancer 
subtypes across the different ethnicities globally [117].
More than two-thirds of the breast carcinomas (approximately 75%) are of luminal subtype 
and initially responsive to anti-estrogens such as tamoxifen. Anti-estrogen resistance is of two 
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types, de novo and acquired, and is likely to develop over time. The absence of both ERα and PR 
expression represents the prevailing mechanism of de novo resistance. The acquired resistance 
is defined by loss of anti-estrogen responsiveness by initially responsive tumors [117]. About 
50–60% of ER-positive tumors respond to the first-line endocrine therapy, while about 40% of 
ER-positive tumors show resistance; the latter correlated with loss of ER expression, changes 
in ERα post-translational modifications, loss of ER-dependent growth, and activation of cross-
talking pathways. About one-third of patients treated with tamoxifen for 5 years will have recur-
rent disease within 15 years [118]. It has been proved that approximately 25% of ER+/PR+, 66% 
of ER+/PR− and 55% of ER−/PR+ breast carcinomas do not respond to anti-estrogens. Several 
studies suggest that loss of ERα can be due to long-term activation of growth factor signaling 
pathways; approximately 30% of the patients show loss of ERα where EGFR/Her-2 activity is 
elevated. Accumulating evidence suggests that several mechanisms act at cellular/molecular 
levels and are likely to be responsible for the endocrine resistance, comprising a major challenge 
today in treating significant percentage of breast cancers by hormone therapy [118].
One contributing factor for the phenomenon of endocrine resistance is the ERα-specific ubiq-
uitin ligases. Re-expression of ERα in ER-negative breast cancer cells can restore sensitivity to 
tamoxifen; restoring the ERα expression by inhibiting ERα-specific ubiquitin ligases provides 
potential novel strategies for restoring tamoxifen sensitivity and thus potential therapeutic 
drugs. Small molecule inhibitors specific to these ubiquitin ligases may overcome tamoxifen 
resistance in breast cancers. In particular, whether ER negativity is a cause or a consequence 
of the disease progression is a million dollar question in this field, but the current understand-
ing of this phenomenon is still at premature stage [118].
4.5.1. GSK3 inhibitors
Glycogen synthase kinase-3 (GSK-3) protects ERα from proteasomal degradation and plays 
a crucial role in ERα protein stabilization and turnover and GSK-3 may be involved in ERα-
mediated transcriptional activation without ERα degradation. Silencing of GSK-3 results in a 
reduction of ERα levels in breast cancer cells due to increased proteasomal degradation, so its 
inhibitors could consist an emerging therapeutic target in the treatment of human breast cancer 
[119]. In a recent study, the pharmacological inhibition of GSK-3 by two novel small molecules, 
9-ING-41 and 9-ING-87, reduced the viability of breast cancer cells; in addition, treatment with 
9-ING-41 enhanced the anti-tumor effect of irinotecan (CPT-11) against breast cancer cells in vitro. 
The same study established two patient-derived xenograft tumor models—from metastatic pleu-
ral effusions obtained from patients with chemo-refractory breast cancer—and demonstrated 
that 9-ING-41 also potentiated the effect of the chemotherapeutic drug CPT-11 in vivo, leading to 
regression of established tumors in mice. These results make GSK-3 inhibitor 9-ING-41 a promis-
ing candidate targeted agent for metastatic breast cancer therapy [120].
4.5.2. RNF31 inhibitors
The atypical E3 ubiquitin ligase RNF31 has an oncogenic role in breast cancer growth through 
facilitating ERα signaling and suppressing P53 signaling, although its ultimate role is not 
thoroughly studied yet. Modulation of ERα levels is one feasible approach to inhibit estrogen 
signaling and subsequently cellular proliferation and possible therapeutic inhibitors targeting 
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RNF31 could constitute a valuable drug for breast cancers. The development of RNF31 inhibi-
tors is ongoing, for example, targeting its function on RBR domain [108].
4.6. BRCA1
The breast and ovarian cancer susceptibility gene BRCA1 is implicated not only in familial 
breast cancers but also in sporadic breast cancers. Approximately 15% of sporadic breast 
cancers belong to the basal-like subtype that expresses basal/myoepithelial cell markers, 
but do not express estrogen receptor, progesterone receptor or HER2 and is associated 
with poor prognosis. Furthermore, the majority of hereditary breast cancers with BRCA1 
mutations display a basal-like phenotype, thus implying the importance of BRCA1 not 
only in familial breast cancers but also in sporadic cancers. BRCA1 is a protein that coor-
dinates a diverse range of cellular pathways to maintain genomic stability and participates 
in multiple cellular supercomplexes, in most of which it exists as a RING heterodimer with 
BARD1 to provide ubiquitin E3 ligase activity that is required for a tumor suppressor func-
tion. Reduced expression of BRCA1, due to mutations or epigenetic inactivation, leads to 
increased risk of breast cancer development. Although BRCA1 is present in all cells, it is 
still not clear why mutations in the BRCA1 gene predispose to breast and ovarian, but not 
to other types of cancer [121].
4.6.1. PARP inhibitors
Poly-ADP-ribose polymerases (PARP) are enzymes that are involved in DNA damage repair 
and their inhibition is a promising strategy for targeting cancers with defective DNA damage 
repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several 
PARP inhibitors are currently in clinical trials in the adjuvant, neoadjuvant and metastatic 
settings for the treatment of BRCA-mutated breast carcinoma (phase 2–3) such as Olaparib 
(AZD2281), Veliparib (ABT-888) and Talazoparib (BMN-673), as single agents or in combina-
tion schemes with chemotherapy and the results are very promising. Also, PARP inhibitor 
activity could be applied to breast cancers without BRCA1/2 mutations and several preclinical 
experiments support this possibility [122]. FDA has approved Lynparza (olaparib) to treat 
ovarian cancers in women who carry mutations in BRCA1 or BRCA2, and who have received 
chemotherapy treatments, but PARP inhibitors are not currently FDA approved for treating 
breast cancer; results from phase 3 using Lynparza has been promising. Nevertheless, more 
investigation needs to be done in order to have more data regarding possible long-term side 
effects [122, 123].
4.7. ErbB2/HER2/neu
Her-2/neu overexpression (gene amplification) is observed in about 20–30% of breast cancer 
patients and is directly linked to deregulated activation of intracellular mitogenic signaling, 
and thus leads to aggressive tumor behavior and resistance to cancer chemotherapy. HER-2 
gene amplification in breast cancer has been associated with tumor invasiveness, accelerated 
angiogenesis, reduced apoptosis, and more progressive regional and distant metastases. So, 
carcinomas that present with a higher-than-average/‘positive’HER-2 status will almost cer-
tainly be more aggressive [124].
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The first approved monoclonal antibody treatment (immune targeted therapy) for breast 
cancer was trastuzumab (Herceptin), which results in significant improvement in patient 
survival when used in combination with chemotherapy in patients with (metastatic) Her-
2/neu-positive carcinoma, both before and after surgery. Specifically trastuzumab blocks 
HER2 receptors from receiving growth signals so it inhibits signaling of MAPK and PI3K 
pathways, promotes cell cycle arrest and induces apoptosis. Herceptin can also help fight 
breast cancer by alerting the immune system to destroy cancer cells onto which it is attached 
and by mediating the internalization and degradation of the Her-2/neu receptor and conse-
quently diminishing its intracellular signaling [125].
Treatments that specifically target HER2 are very effective and the prognosis for HER2-
positive breast cancer is actually quite good. Other treatments that target HER2/neu recep-
tor include Lapatinib (Tykerb), Pertuzumab (Perjeta) and/or Ado-trastuzumab emtansine 
(Kadcyla). Nevertheless, the primary or acquired resistance as well as the side effect toxicity 
of trastuzumab, for example, cardiac dysfunction have led to the investigation of other mol-
ecules that could downregulate HER2/neu. Several new medications are being developed are 
under clinical trials [126].
4.7.1. Quercetin
The natural product quercetin (3,5,7,3′,4′-pentahydroxyflavone) is orally bioavailable and is 
a flavonoid found in many fruits and vegetables. Previous research has shown that quercetin 
has anti-tumor, anti-inflammatory, anti-allergic and anti-viral activities and has been shown 
to be protective against breast cancer in animal model. A recent study showed that querce-
tin decreased the level of Her-2/neu protein in time- and dose-dependent manner and also 
inhibited the downstream survival PI3K-Akt signaling pathway in Her-2/neu-overexpress-
ing breast cancer SK-Br3 cells. In addition, this product-induced polyubiquitination of Her-2/
neu. The carboxyl terminus of Hsc70-interacting protein (CHIP), a chaperone-dependent E3 
ubiquitin ligase, was found to play a crucial role in the quercetin-induced ubiquitination of 
Her-2/neu. Inhibition of tyrosine kinase activity of Her-2/neu by quercetin could indicate a 
lateration in the Her-2/neu structure which promotes CHIP recruitments and downregula-
tion of Her-2/neu. So this agent could be one more promising drug to treat Her-2/neu-over-
expressing cancers [127].
4.7.2. Afatinib
The novel next-generation tyrosine kinase inhibitors (TKIs), afatinib and neratinib, were 
designed to overcome the resistance by targeting multiple HER family members and irrevers-
ibly binding the targets. Despite the encouraging results of the afatinib monotherapies, mul-
ticenter international trials are still ongoing for their evaluation. Neratinib has been shown 
to be an effective treatment in the metastatic, neoadjuvant and adjuvant setting, both as a 
single agent or in combination with cytotoxic agents [128]. Recently, in July 2017, the US FDA 
approved neratinib for the extended adjuvant treatment of early stage HER2- overexpressed/
amplified breast cancer, to follow adjuvant trastuzumab-based therapy [111].
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4.8. TRAIL receptors
4.8.1. rhTRAIL
Drugs based on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is antici-
pated to be one of the most effective cancer treatments, however, resistance to TRAIL therapy 
remains a challenge and TRAIL combinations have been experimented with for over 10 years 
to induce synergism or sensitize resistant cancer cells. TRAIL is characterized by its ability to 
induce apoptosis in tumor cells but not in normal cells, thus qualifying as a potential drug 
specific for different types of cancer, including breast, bladder, lung and liver; the develop-
ment of recombinant human TRAIL (rhTRAIL) as a promising therapy for different types of 
human cancer. However, a majority of breast cancer cell lines exhibit resistance to TRAIL 
treatment due to upregulation of pro-apoptotic proteins, downregulation of anti-apoptotic 
proteins and/or upregulation of death receptors 4 and 5. To overcome TRAIL resistance, a co-
treatment option has been studied using the natural compound Quercetin [129]. One recent 
studies findings suggest that the co-treatment of Quercetin and rhTRAIL has the potential to 
be an anti-breast cancer therapeutic strategy, by enhancing pro-apoptotic and anti-prolifera-
tive effects in hormone dependent and triple negative breast cancer cells [130].
4.9. NEDD4
NEDD4 (neural precursor cell expressed, developmentally downregulated 4) is an E3 ubiquitin 
protein ligase that has been found to target numerous substrates for its biological functions and 
plays a pivotal role in the development and progression of human cancers; it is observed that 
NEDD4 expression was increased in breast cancer [131]. Additionally, it acts as an E3 ligase of 
PTEN—a tumor suppressor gene—catalyzing poly-ubiquitination of PTEN protein in cells and 
leading to its proteolysis. It has been reported to negatively regulate PTEN protein levels in car-
cinomas of the prostate, lung and bladder, but recent studies showed either no association or a 
positive correlation at the protein and transcript levels, regarding NEDD4’s effect on PTEN in 
the breast cancer; this suggests that NEDD4 is not responsible for the frequent downregulation 
of PTEN protein in human breast carcinoma [132]. In general, NEDD4 could be a legitimate 
target for designing new drugs against human malignancies, although surprisingly, NEDD4 
inhibitors have not been discovered so far. More investigation on this pathway could lead to 
the development of this E3 ubiquitin ligase inhibitors such as beta-TRCP that could contribute 
to the decrease of abundant NEDD4 oncoprotein levels by its destruction [133].
4.10. DUBs
Ubiquitination is reversible, like most regulatory cellular processes, and the enzymes that 
reverse protein ubiquitination are collectively known as deubiquitinases (DUBs). The mam-
malian genome encodes around 100 DUBs that are categorized into five classes, four of which 
are thiol proteases including ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific pro-
teases (USPs), ovarian tumor domain DUBs and machado Joseph domain DUBs. The fifth class 
comprises JAB1/MPN metalloenzyme, which functions as a zinc finger metalloprotease [134].
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4.10.1. USP inhibitors
Generally, a number of regulate processes associated with cell proliferation and apoptosis, and 
as such represent candidate targets for cancer therapeutics. The majority of DUBs is cysteine pro-
teases and is likely to be more “druggable” than E3 ligases. Ubiquitin-specific proteases (USPs) 
are one class of DUBs implicated in breast cancer by transforming growth factor beta (TGF-
β) signaling; the latter has a well-documented role in mediating epithelial-to-mesenchymal 
transition (EMT), tumor progression and metastasis in breast cancer. Specifically, the deubiq-
uitinases USP4, USP9X, USP9Y, USP10, USP11, USP15, USP25 and USP32, but also DUB3 are 
upregulated/overexpressed in human breast cancer [134].
Several inhibitors have been developed against USPs such as HBX 41,108, b-AP15 and pimo-
zide. WP1130 is a partially selective DUB inhibitor that induces apoptosis in cells through 
rapid accumulation of poly-ubiquitinated proteins that targets USP5, USP9X and USP14, 
among others. USP9X inhibition by WP1130 in tumorigenic human breast cancer cell lines 
inhibits their growth and USP9X knockdown in all triple negative breast cancer cell lines 
caused apoptosis induction, so WP1130 and its derivatives could be a significant therapeu-
tic agents in the treatment of breast cancer [134]. Moreover, the specific inhibitor WP1130 
binds to DUB3 and inhibits the DUB3-mediating Snail1 stabilization in vitro and in vivo, as 
it blocked tumor cell migration, invasion and suppressed CSC-like properties, providing a 
proof for therapeutic development of small molecules to inhibit the activity of DUB3 in meta-
static breast cancer. These data strengthen the view that DUB3 is an ideal candidate for the 
development of inhibitors for cancer treatment based on its dual role in regulating cell growth 
and metastasis [135].
b-AP15, an inhibitor for both UCH37 and USP14, was able to accumulate ubiquitinated sub-
strates and had excellent efficacy in different in vivo solid tumor models, as well as an acute 
myeloid leukemia model. On the contrary, a more selective USP14 inhibitor, IU1, had an 
opposite effect by enhancing degradation of target proteins, leading to a dose-dependent 
reduction in overexpressed proteins including Tau, showing that selective inhibition of differ-
ent proteasomal DUBs may have different outcomes; nevertheless inhibition of proteasomal 
DUBs is worthy of investigation as a potential anti-cancer therapy [136].
4.11. Antiestrogens (Tamoxifen, Raloxifene, Fulvestrant, Letrozole)
Antiestrogens are classified as selective estrogen receptor modulators (SERMs), for example, 
tamoxifen and raloxifene—that have antagonist activity in breast and partial agonist activity 
in uterus and bones—and as pure antiestrogens, for example, fulvestrant; the latter acceler-
ate ERa proteasomal degradation so they represent selective estrogen receptor downregula-
tors (SERDs). Tamoxifen is the first clinically approved antiestrogen and remains the standard 
adjuvant treatment for all stages of primary breast carcinoma [137]. It has been shown that 
ubiquitin ligase c-Cbl is involved (enhances) in tamoxifen-induced apoptosis of MCF-7 cells 
[138]. Nevertheless, significant number of these patients develop resistance to tamoxifen, 
which in addition shows negative side effects, such as thromboembolic events and endome-
trial cancer. Raloxifene has 76% of effectiveness of tamoxifen at reducing incidence of invasive 
breast cancer with less incidence of endometrial cancer. Fulvestrant acts via different molecular 
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mechanism consisting in increased ERa turnover through the ubiquitin—proteasome pathway 
in ERa+ breast cancer cells [137]. Finally, it has been shown that inhibition of ubiquitin conju-
gating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to letrozole—an 
aromatase inhibitor—tamoxifen etc. [139]. All the above-mentioned antiestrogen drugs are 
FDA-approved and have been used in HR+ (advanced/metastatic) breast carcinomas, includ-
ing for reducing cancer risk (tamoxifen, raloxifene) [111].
5. Conclusion
Ubiquitination involves the attachment of ubiquitin to numerous target proteins leading to 
regulation of their half-life, localization, activity and conformation. Recent years’ analysis sug-
gests that ubiquitin plays a very important role in several signaling and cell regulatory events 
in malignancies, including breast cancer, which remain the commonest carcinoma and second 
cause of death among women worldwide. Targeting molecules of the ubiquitination system 
is very promising for the treatment of breast cancer, as well as for other neoplasms. Although 
many potential targets that belong to this category are under trials, only few have already 
taken FDA approval and are used as therapeutic drugs so far such as ribociclib (Kisqali) and 
palbociclib (PD-0332991). Suberoylanilide hydroxamic acid (SAHA) also known as vorinostat, 
romidepsin (Istodax) and depsipeptide are HDAC inhibitors that are being used among others 
in clinical trials for treating breast malignancies, but also other molecules such as ganetespib and 
olaparib; yet, more targets are studied as possible treatment candidates, for example, nutlin-3 
and quercetin (Table 1). In spite of the fact that drug targets belonging to the spectrum of ubiq-
uitin system are very promising, a lot need to be done by future studies on their development 
and clinical application, either as monotherapy or as combination therapy for breast cancer.
Drug-related 
molecule
Current phase
Molecule 
selection/design 
production
Preclinical modeling—
in vitro/in vivo (cell 
lines, xenografts)
Clinical trials FDA approved
P53/MDM2 Beclin 1 inducer 
or inhibitor
Nutlin-3 Hsp90 Inhibitors 
(Geldanamycin, 
17-AAG, Ganetespib)
RING finger 
protein 31 
inhibitors 
(RNF31i)
Histone Deacetylase 
Inhibitors (Vorinostat/
SAHA, Romidepsin/
Depsipeptide, 
Belinostat)
CDKs–CDIs CDK4/6 inhibitors (Palbociclib, 
Ribociclib, Abemaciclib)
SCF complex 
–SKP2/p27
Curcumin, lycopene, 
pentagalloylglucose, 
quercetin, ATRA, garlic 
acid, EGCG, SKP2 siRNA
Histone H2B USP44 inhibitors USP44 inhibitors
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Abbreviations
CKIs  Cdk kinase inhibitors
DNA  Deoxyribonucleic acid
DUBs  Deubiquitinating enzymes
FDA  Food and drug administration
HR  Homologous recombination
Hsp90  Heat shock protein 90
MDM2  Murine double minute 2 homolog/oncoprotein
NEDD4  Neuronally expressed developmentally downregulated 4
NHEJ  Non-homologous recombination
Drug-related 
molecule
Current phase
Molecule 
selection/design 
production
Preclinical modeling—
in vitro/in vivo (cell 
lines, xenografts)
Clinical trials FDA approved
ER RNF31 inhibitors GSK-3 inhibitors (9-ING-
41, 9-ING-87)
BRCA1 PARP inhibitors 
(Olaparib, Veliparib, 
Talazoparib)
ErbB2/HER2/neu Quercetin Tyrosine kinase 
inhibitors (Afatinib)
Tyrosine kinase inhibitors 
(Lapatinib, Neratinib)
Monoclonal antibodies 
(Trastuzumab, Ado-
trastuzumabemtansine, 
Pertuzumab)
TRAIL receptors rhTRAIL (co-treatment 
of Quercetin)
NEDD4 NEDD4 
inhibitors 
(beta-TRCP)
DUBs DUB3 inhibitors USP inhibitors (WP1130, 
b-AP15)
Antiestrogens Tamoxifen, Raloxifene, 
Fulvestrant, Letrozole
Table 1. Drugs/therapeutic agents for breast cancer related to ubiquitin system.
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PCNA  Polymerase DNA
PTM  Post-translational modifications
RING  Really interesting new gene
RNF31  RING finger protein 31
RTK  Tyrosine kinase receptor
SCF  SKP1-Cullin 1-F-box
SKP1  S-phase kinase-associated protein 1
Ub  Ubiquitin
UPP  Ubiquitin proteasome pathway
UPS  Ubiquitin/proteasome system
HR+  Hormone receptor-positive
H2Bub1  Monoubiquinated histone H2B
USP44  Ubiquitin-specific protease 44
TNBC  Triple negative breast cancer
CSC  Cancer stem cells
ATP  Adenosine triphosphate
ER  Estrogen receptor
PR  Progesterone receptor
HER2  Human epidermal growth factor receptor2
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